# Dose-escalation Study of Lupartumab Amadotin (BAY1129980)

> **NCT02134197** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 69 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Lupartumab Amadotin (BAY1129980)

## Key facts

- **NCT ID:** NCT02134197
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-22
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-08-30
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134197, "Dose-escalation Study of Lupartumab Amadotin (BAY1129980)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02134197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*